Business Wire

AMADIS

29.9.2020 13:57:09 CEST | Business Wire | Press release

Share
Amadis Leverages Nexo Standards to Simplify Global Payment Acceptance

Amadis , a payment software and consulting services provider, today announced a streamlined path for North American and international merchants to migrate to the nexo global payment standard, the most comprehensive set of global payment acceptance protocols on the market today. By integrating nexo’s messaging protocols, standards and specifications into its Arkos universal payments acceptance software, Amadis provides “plug-and-play” universal payment software that enables customers to quickly accept new payment types, independent of equipment, technology or geography.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200929005023/en/

Amadis has helped a diverse range of banking, retail and transport customers deploy nexo-based applications, enabling customers to future-proof their payment systems, while lowering development time and accelerating time to market. With Amadis’ Arkos product, an EMV middleware that manages all the card acceptance processing, customers can rapidly migrate to nexo and vastly reduce their custom development requirements, enabling companies to substantially reduce time to market, risks and costs for each unique payment solution implementation. Arkos can manage any type of equipment (standalone, PINPads, unattended, mobile) and devices while:

  • Integrating US processing rules (debit network selection; low value payments)
  • Providing central management and reporting
  • Meeting M-TIP, ADVT Pre-certified EMV requirements

“By editing the Amadis Arkos software using nexo protocols, we ensure our clients have the same common interoperable interface and protocol across the globe that breeds innovation at the point of contact,” said Emmanuel Haydont, CEO, and co-founder of Amadis. “By using nexo protocols, we help our customers drastically reduce time to market and cost of ownership, while enabling them to free themselves from unnecessary technical dependencies and provide a pathway that better future-proofs merchants as payments continue to evolve.”

nexo standards is the international association enabling global interoperability in payment acceptance. Its membership is expanding rapidly across continents, with members from several countries including the United States, Canada, China, India, Japan, Russia, and Saudi Arabia, further cementing the global interest in its standards and its truly international reach.

Unlike proprietary solutions that lock companies into using proprietary host interfaces, terminal management systems (TMS), platforms or operating in a certain geography, nexo is an open standard that guarantees multiple interoperabilities: cross border, platform, host, market segment and others. nexo standards enables companies to innovate on top of its specifications and protocols, removing both the significant complexity from the technical integration as well as the implementation challenges companies face as they expand acceptance of new payment types from devices in new markets. The nexo association provides open standards and protocols that guarantee cross-border interoperability.

“Market demand for nexo standards is higher than ever before. In response, active members such as Amadis are making significant progress in their deployment and adoption strategies,” comments Jacques Soussana, Secretary-General at nexo standards. “With the combination of our specifications, protocols, implementation guidelines, collaborative working groups, and testing and certification support, we are providing members with the tools to build and validate their solutions, fast-tracking their path to deployment. The global adoption of nexo standards is fast becoming a reality.”

Amadis’ global customers require payment acceptance solutions that are secure and ensure optimized operations, while allowing for best management of future-proofing needs in the near and long-term. nexo standards is the international association enabling global interoperability in payment acceptance. With the recent global stresses the economy and industries have faced, it has become imperative that solution providers seek out standards such as nexo that allow businesses to operate more efficiently and expand globally.

*EMV ® is a registered trademark in the U.S. and other countries and an unregistered trademark elsewhere. The EMV trademark is owned by EMVCo, LLC

About Amadis

Amadis is a privately-held division of Maxim Integrated. Amadis is a leader in payment software technology, with its software running on more than 10 million devices worldwide. The company provides state-of-the-art software editing and development solutions for global merchants, payment device manufacturers and service providers. Amadis provides merchants with the industry’s broadest range of payment processing options using custom or commercially available technology, independent of hardware or geography. The company brings an elite, experienced software team to the industry and enables solutions for international merchants in over 23 countries. Learn more at www.amadis.ca .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release

Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa

EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release

EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia

Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release

Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting

FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release

FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease

Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release

Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye